Vorasidenib is an oral medication used in the treatment of certain types of cancer, specifically IDH1/2-mutant gliomas. It is an inhibitor of the isocitrate dehydrogenase (IDH) enzymes, which are involved in cellular metabolism.
Vsquare is a leading innovator in pharmaceutical reference standards. We supply high-quality Reference Standards of Vorasidenib, pharmacopeial and non-pharmacopeial Vorasidenib impurities, metabolites, stable isotope products, and nitrosamines (N-NO products). Vorasidenib impurities reference standards are useful in pharmaceutical research. They are useful in product development, ANDA and DMF filing, quality control (QC), method validation, and stability studies. It is also useful in the identification of unknown impurities and the assessment of genotoxic potential.
Vorasidenib-related products are thoroughly characterized. Vorasidenib products are supplied with detailed COA & analytical data meeting regulatory compliance. We can also provide EP/USP traceable standards based on your requirements. The supplied products are re-tested at regular intervals.
-292x116.png "Vorasidenib")
